Tue, Sep 16, 2014, 12:28 AM EDT - U.S. Markets open in 9 hrs 2 mins


% | $
Quotes you view appear here for quick access.

Endocyte, Inc. (ECYT) Message Board

paintball_is_stellar 7 posts  |  Last Activity: Sep 13, 2014 10:44 AM Member since: Jun 20, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • paintball_is_stellar paintball_is_stellar Sep 13, 2014 10:44 AM Flag

    I think with the complications that Endocyte experienced with the PROC drug, Merck wasn't willing to wait for it to get fixed. They instead decided to shed several of their partnerships and buy a company. They withdrew from the Endocyte partnership without knowing what the NSCLC results were.

  • paintball_is_stellar by paintball_is_stellar Sep 9, 2014 8:54 AM Flag

    Anyone have any info on how reputable this upgrade? Just curious more than anything?

  • paintball_is_stellar by paintball_is_stellar Sep 4, 2014 11:17 AM Flag

    I dialed in and listened to the conference yesterday. Overall, I thought it was pretty informative but also more or less a status update. Couple things to note:
    1) Merck discontinued the partnership along with other companies that were in line with their business priorities. They did this without seeing the data that will be presented later this month.
    2) Endocyte was approached by other partners but has told them they want to get a better grasp of the data that they have before pursuing a partnership.
    3) Tubulysin in the final cohort of dosage analysis. It has in some cases shown to cure cancer. If toxicity is not an issue after this final cohort they plan to continue the trial in about 6 different types of cancers with ovarian being one of them.
    Ultimately though, we are still a ways out but a lot of potential as long as everything stays safe. Tubulysin is 20 times more powerful than Vintafolide so the results should be 20 times better. :) Here's to hoping. Lots of potential here and if they can finally score a touchdown this company could be very profitable. Long for a while!

  • paintball_is_stellar by paintball_is_stellar Aug 5, 2014 4:53 PM Flag

    I'm long this stock and believe in the company. I am not however very confident that the NSLC data will prove to be positive. I think the company will cut vintafolide and move onto Tubulysin. I do hope for good news since I'm horribly in the red, but I'm not holding my breath. Could see the mid 5's before something significant comes from Tubulysin.

  • paintball_is_stellar by paintball_is_stellar Jul 30, 2014 8:46 AM Flag

    What say you about the CC and data?

  • Reply to


    by paintball_is_stellar Jun 25, 2014 8:43 PM
    paintball_is_stellar paintball_is_stellar Jun 27, 2014 1:00 PM Flag

    Appreciate the input. I wasa #$%$ and held all the way through this positive news. Never thought the bottom would drop out on the phase III since it seemed to be doing well.

    I'm not exactly feeling confident in the lung cancer trial. Tubulysin as you said seems promising. I think the technology is good and works, but they have an issue with the medicine part. This is a rough place to be.

  • paintball_is_stellar by paintball_is_stellar Jun 25, 2014 8:43 PM Flag

    You around still? Would be interested in your thoughts on everything. Thanks!

8.15-0.43(-5.01%)Sep 15 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT